# A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease

> **NCT01603069** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 51 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** AZD3241 300 mg BID
- **DRUG:** AZD3241 600 mg BID
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01603069
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2013-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01603069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01603069, "A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01603069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*